TYRA Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: Tyra Biosciences

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

3 months ago - By: Tyra Biosciences

Tyra Biosciences Announces Participation at Upcoming Investor Events

3 months ago - By: Zacks Investment Research

Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?

3 months ago - By: The Motley Fool

Tyra Biosciences Narrows Loss in Q2

3 months ago - By: Tyra Biosciences

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

9 months ago - By: Tyra Biosciences

Tyra Biosciences to Present at Upcoming Investor Conferences

4 months ago - By: Tyra Biosciences

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

4 months ago - By: Tyra Biosciences

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

6 months ago - By: Tyra Biosciences

Tyra Biosciences to Participate at Upcoming Investor Conferences

6 months ago - By: Tyra Biosciences

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

7 months ago - By: Benzinga - Mentions: HAL NOC USAR FPH ...

Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

a year ago - By: Tyra Biosciences

Tyra Biosciences to Present at Upcoming Investor Conferences

7 months ago - By: Benzinga - Mentions: PTN IBIO OM SXTC ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

7 months ago - By: Tyra Biosciences

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

9 months ago - By: Tyra Biosciences

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

10 months ago - By: Tyra Biosciences

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

10 months ago - By: Tyra Biosciences

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

a year ago - By: Tyra Biosciences

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

a year ago - By: Tyra Biosciences

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

a year ago - By: Tyra Biosciences, Inc.

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

a year ago - By: Tyra Biosciences

TYRA BIOSCIENCES INC (TYRA) Stock News

TYRA Latest News, Press Relases and Analysis

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Tyra Biosciences Announces Participation at Upcoming Investor Events

Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?

Tyra Biosciences Narrows Loss in Q2

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

Tyra Biosciences to Participate at Upcoming Investor Conferences

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Tyra Biosciences to Present at Upcoming Investor Conferences

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET